Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects

This study has been terminated.
(During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of brainstem toxicity/encephalopathy during lidocaine/saline infusion)
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 23, 2009
Last updated: July 5, 2012
Last verified: February 2011
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2009
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)